Phase I/Ib Study of Nivolumab in Combination With Therasphere (Yttrium-90) in Patients With Advanced Hepatocellular Carcinoma
Phase of Trial: Phase I
Latest Information Update: 29 Jul 2016
At a glance
- Drugs Nivolumab (Primary) ; Yttrium-90 (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- 26 Jul 2016 Planned primary completion date changed from 1 Jul 2018 to 1 Jul 2019.
- 26 Jul 2016 Status changed from not yet recruiting to recruiting.
- 22 Jul 2016 New trial record